Clariant announces strategic investment in Haelixa

As part of this cooperation, Clariant has acquired a minority stake in Haelixa to support the further development of Haelixa's DNA-based tracing and tagging technology. "Haelixa's technology shows great promise in several product categories and applications which are relevant to Clariant. We are therefore delighted to work with Haelixa and are committed to further developing and commercializing this exciting technology", said Richard Haldimann, Clariant's Head of New Business Development.

For Clariant, the cooperation with Haelixa exemplifies its commitment to focus on innovation through R&D as part of its holistic approach to creating value for all stakeholders. In addition to the extensive R&D activities conducted in-house, including at its Innovation Center in Frankfurt (Germany), Clariant recognizes the importance of open innovation as a method to access promising technologies developed by other large corporations, startups and universities.

Haelixa provides provides DNA-based reliable markers to label products and raw materials to ensure supply chain integrity and greater resource productivity. In addition the company offers innovative reservoir assessment solutions for improved and sustainable asset exploitation and development in the oil & gas and geothermal industry.

Clariant is a globally leading specialty chemicals company, based in Muttenz near Basel/Switzerland. On 31 December 2017 the company employed a total workforce of 18 135. In the financial year 2017, Clariant recorded sales of CHF 6.377 billion for its continuing businesses. The company reports in four business areas: Care Chemicals, Catalysis, Natural Resources, and Plastics & Coatings. Clariant’s corporate strategy is based on five pillars: focus on innovation through R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.

(SK)